Why Revolution Medicines Stock Is Crashing Today
Shares of Revolution Medicines (NASDAQ: RVMD) were crashing 42.5% lower as of 11:13 a.m. ET on Monday. The steep decline came after the oncology company presented results on Sunday for RMC-6236 from a phase 1 study targeting the treatment of non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) at the European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain. Expectations appeared to be high for Revolution Medicines and for RMC-6236 going into ESMO, as evidenced by the biotech stock soaring to more than 40% year to date last week. Shares of Revolution Medicines (NASDAQ: RVMD) fell 42.5% following the presentation of results for RMC-6236 from a phase 1 study at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. The company's stock has risen by over 40% year to date.
Opublikowany : 2 lata temu za pomocą Keith Speights, The Motley Fool w Finance
Shares of Revolution Medicines (NASDAQ: RVMD) were crashing 42.5% lower as of 11:13 a.m. ET on Monday. The steep decline came after the oncology company presented results on Sunday for RMC-6236 from a phase 1 study targeting the treatment of non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) at the European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain. Expectations appeared to be high for Revolution Medicines and for RMC-6236 going into ESMO, as evidenced by the biotech stock soaring to more than 40% year to date last week.
Tematy: Markets